Abstract Background Second-generation antipsychotics (SGAs) are a mainstay therapy for
schizophrenia. SGA-treated patients present higher risk for weight gain, dyslipidemia and …

Olanzapine (OLA), a widely used second-generation antipsychotic (SGA), causes weight
gain and metabolic alterations when administered orally to patients. Recently, we …

The concurrent use of several medications is a common practice in the treatment of complex
psychiatric conditions. One such commonly used combination is aripiprazole (ARI), an …

Gestational diabetes (GDM) is characterized by a glucose tolerance disorder. This may first
appear during pregnancy or pre-exist before conception as a form of prediabetes, but there …

Antipsychotics used to treat schizophrenia can cause drug-induced liver injury (DILI),
according to the Roussel Uclaf Causality Assessment Method. The role of oxidative stress in …

Second-generation antipsychotics (SGAs), in particular, olanzapine and clozapine, have
been associated with the development of type 2 diabetes mellitus (T2D) and metabolic …

Atypical antipsychotics (AAPs) are commonly prescribed drugs in the treatment of
schizophrenia, bipolar disorder and other mental diseases with psychotic traits. Although the …

Olanzapine (OLA) is a highly obesogenic second-generation antipsychotic (SGA). Recently
we demonstrated that, contrarily to OLA oral treatment, intraperitoneal (ip) administration …

The utilization of atypical antipsychotics (AAPs) often leads to metabolic syndrome (MetS) in
schizophrenia (SZ) patients. Macrophage migration inhibitory factor (MIF) is an important …

The decline of urethral function with advancing age plays a major role in urinary
incontinence in women, impairing quality of life and economically burdening the health care …